Edition:
India

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

3.31USD
16 Feb 2018
Change (% chg)

$-0.12 (-3.50%)
Prev Close
$3.43
Open
$3.40
Day's High
$3.48
Day's Low
$3.31
Volume
3,256
Avg. Vol
15,033
52-wk High
$9.38
52-wk Low
$2.85

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 2.98
Market Cap(Mil.): $36.27
Shares Outstanding(Mil.): 7.51
Dividend: --
Yield (%): --

Financials

BRIEF-Baker Bros Advisors LP Reports 8.9 Pct Passive Stake In Tonix Pharmaceuticals Holding As Of Dec 31, 2017 - SEC Filing

* BAKER BROS ADVISORS LP REPORTS 8.9 PERCENT PASSIVE STAKE IN TONIX PHARMACEUTICALS HOLDING AS OF DEC 31, 2017 - SEC FILING Source text: (http://bit.ly/2HcDj6B) Further company coverage:

14 Feb 2018

BRIEF-Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent For The Active Ingredient In Tonmya

* TONIX PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE FOR NEW U.S. PATENT FOR THE ACTIVE INGREDIENT IN TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) Source text for Eikon: Further company coverage:

23 Jan 2018

BRIEF-Tonix Pharmaceuticals Appoints Jessica Morris As CEO

* TONIX PHARMACEUTICALS APPOINTS JESSICA MORRIS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL

* TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE

12 Dec 2017

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

07 Nov 2017

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

17 Oct 2017

BRIEF-Tonix Pharmaceuticals enters into purchase agreement, registration rights agreement with Lincoln Park Capital Fund

* On Sept. 28 co entered into purchase agreement, registration rights agreement with Lincoln Park Capital Fund LLC

30 Sep 2017

BRIEF-Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya

* Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya® (cyclobenzaprine hcl sublingual tablets) Source text for Eikon: Further company coverage:

15 Sep 2017

BRIEF-Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors

* Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors Source text for Eikon: Further company coverage:

14 Sep 2017

BRIEF-Tonix Pharmaceuticals presents additional phase 2 clinical results, ongoing phase 3 trial design of Tonmya at 2017 Military Health System Research Symposium

* Tonix Pharmaceuticals presented additional phase 2 clinical results in military-related PTSD and design of ongoing phase 3 trial at the 2017 Military Health System Research Symposium

30 Aug 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.15 +1.92
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF79.68 --
AstraZeneca plc (AZN.L) 4,712.50 -27.00
GlaxoSmithKline plc (GSK.L) 1,308.60 -10.00

Earnings vs. Estimates